Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 114 results found. Search for [ COVID-19 vaccine Gamaleya ]

Results 1 to 21 of 114
Manoj Sharma
May 17, 2021
The current vaccine makers, Serum Institute and Bharat Biotech, alone won't be able to meet the demand. There are other players too in vaccine production, and they should be able to cater to the demand in the months ahead


Vivek Dubey
May 6, 2021
\"The cost of the Sputnik Light vaccine globally will be less than $10 [around Rs 730], while it has simple storage requirements, at 2-8 degrees Celsius, which provide for easy logistics\"


BusinessToday.In
May 1, 2021
Developed by Russia's Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V was approved by Indian drug regulator last month.


Reuters
April 27, 2021
Anvisa's five-strong board voted unanimously not to approve the Russian vaccine after technical staff had highlighted \"inherent risks\" and \"serious\" defects, citing a lack of information guaranteeing its safety, quality and effectiveness


BusinessToday.In
April 25, 2021
The Hyderabad-based vaccine manufacturer has submitted updated accelerated and real-time stability data of Coaxin along with the justification for the extension of shelf life


BusinessToday.In
April 13, 2021
India is the leading production hub for Sputnik V. RDIF has signed pacts with Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech to produce over 850 million doses per year


BusinessToday.In
New Delhi, April 12, 2021
Russia's Sputnik V COVID-19 vaccine, with an effectiveness of 91.6 per cent, has been approved for restricted use in India, sources within the drug regulator's office confirmed the development on Monday. The approval to the vaccine was given based on 'very strong immunogenicity data'. Sputnik V has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. The vaccine demonstrated an efficacy rate of 91.6 per cent in the interim analysis of the phase 3 clinical trial in Russia. In February 2021, Dr Reddy's applied for the emergency use of the Russian vaccine in India. Watch the video for more.Also Read: Russia's COVID-19 vaccine Sputnik V gets govt's nod


BusinessToday.In
April 12, 2021
Developed by Russia's Gamaleya national center of epidemiology and microbiology, Sputnik V is the third COVID-19 vaccine approved by the Subject Expert Committee (SEC) after Covishield and Covaxin


BusinessToday.In
April 9, 2021
The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study.


BusinessToday.In
April 6, 2021
Share of the pharma firm rose 19.99% to Rs 220.85 against previous close of Rs 184.40 on BSE. The stock opened with a gain of 15.68% at Rs 212.90


Rashi Bisaria
New Delhi, April 6, 2021
COVID-19 vaccination: Uddhav Thackeray asks PM Modi to reduce eligible age to 25 yrsMaharashtra Chief Minister Uddhav Thackeray has written a letter to Prime Minister Narendra Modi asking to reduce the age for getting COVID-19 vaccination to 25 years. Saying that the second wave of the coronavirus is much stronger than the first wave in the state, Thackeray said Maharashtra is taking up vaccination at a rapid pace and is the number 1 state in the country in terms of COVID-19 vaccine doses adm...


BusinessToday.In
April 5, 2021
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF.


BusinessToday.In
March 19, 2021
Stelis and the RDIF plan to start supplying the vaccine doses in the third quarter of this year, said Strides Pharma. It is yet to be ascertained which countries the doses would go to


BusinessToday.In
March 16, 2021
Share of Gland Pharma touched an all-time high of Rs 2,784.45, rising 9.54% against previous close of Rs 2,541 on BSE


BusinessToday.In
March 16, 2021
COVID-19 vaccine: Gland Pharma said that the production of Sputnik V is expected to commence from third quarter of 2021 for estimated delivery starting from fourth quarter of 2021


PB Jayakumar
March 3, 2021
So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy


BusinessToday.In
February 20, 2021
Russia has already approved two COVID-19 vaccines, Sputnik V and EpiVacCorona, which were also granted approval before seeing any late-stage trial results


BusinessToday.In
February 19, 2021
As part of the review process, Dr Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 21st February 2021.


BusinessToday.In
February 15, 2021
Earlier, Dr Reddy's had said it expects to roll out Sputnik V vaccine in India in March via Emergency Use Authorisation (EUA) after the completion of Phase 3 trials.


BusinessToday.In
February 3, 2021
Earlier, The Lancet had stated that Russia's experimental COVID-19 vaccine Sputnik V is 91.6 per cent affective against coronavirus infection. These results are based on Phase 3 trials of the vaccine in which 20,000 people had participated


PAGES 1 OF 6  12345